{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-107268","form_type":"8-K","ticker":"CUE","cik":"0001645460","company_name":"Cue Biopharma, Inc.","filed_at":"2025-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.550230+00:00","generated_at":"2026-05-17T14:37:05.530587+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Cue Biopharma Q2 net loss $8.5M; BI deal with $12M upfront, $345M milestones","bullets":["Net loss $8.5M ($0.09/share) vs $10.2M in Q2 2024; collaboration revenue $3.0M.","Announced collaboration with Boehringer Ingelheim for CUE-501: $12M upfront, up to $345M milestones.","Received FDA Pre-IND feedback supporting CUE-401 IND for autoimmune disease.","CUE-101 Phase 1 data: 50% ORR, 88% 12-mo OS, median OS 32 months in HPV+ HNSCC.","Raised ~$20M via public offering; cash position $27.5M at June 30."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-107268","json":"https://secwatch.observer/filing/0000950170-25-107268.json","markdown":"https://secwatch.observer/filing/0000950170-25-107268.md","text":"https://secwatch.observer/filing/0000950170-25-107268.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645460/000095017025107268/0000950170-25-107268-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645460/000095017025107268/cue-20250812.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T14:37:05.530587+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}